Compare McCormick & Company, Incorporated (MKC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Novartis AG — how do they compare? McCormick & Company, Incorporated trades at $45.94 (market cap $12.20B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 22.5× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (4.24%). Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Novartis AG for 82 Days on average.
| MKC | NVS | |
|---|---|---|
Market Cap | $12.20B | $274.00B |
Volume | 4,117,008 | 1,852,137 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $168.62 |
52-Week Low | $44.14 | $121.80 |
Typical Hold Time | 67 Days | 82 Days |
Enterprise Value | $16.88B | $315.32B |
Dividend Yield | 4.24% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.94, up 1.19% today, with a bearish technical signal but strong fundamentals. Recent Q3 2026 earnings beat estimates with $0.86 EPS, driven by 17% sales growth and margin expansion. The stock appears undervalued with a P/E of 8.18 and offers a dividend yield. Cash flow trends show operational strength despite a net outflow in 2025.
The outlook is mixed: solid earnings growth and a $53.50 consensus price target suggest upside, but technical weakness and competitive pressures pose risks. Investor sentiment is cautious with a 'Hold' analyst consensus. Key catalysts include continued margin improvement and integration of recent acquisitions.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
